Laurus Labs expands margins as quarterly profit rises 21%
Operating margin reached a multi-quarter high, while lower interest and tax costs supported profit growth despite sharply lower other income.
Filed 30 Apr 2026, 15:15 IST · Laurus Labs Ltd (LAURUSLABS)
Key takeaways
- Consolidated operating margin rose 3.82 percentage points year on year to 28.27% as revenue grew 5.31% while expenses declined 0.02%.
- Consolidated net profit increased 21.19% year on year, helped by a 3.23-percentage-point lower tax rate and a 28.30% fall in interest costs.
- The stock slipped 0.47% on the results day, a smaller move than its 3.08% median absolute reaction after the past eight results.
Price around the results
Operating leverage lifts Q4FY26 profit
Laurus Labs reported consolidated revenue growth of 5.31% year on year, but expenses fell 0.02%, driving a 21.76% increase in operating profit. Net profit rose 21.19% to Rs 282.09 cr, with EPS up 19.12% to Rs 5.17. Other income fell 79.15% year on year and contributed only 3.31% of pre-tax profit, so the quarter's profit growth was not materially dependent on that item.
Margin improvement continues for a fourth quarter
Operating margin expanded 3.82 percentage points year on year and 1.27 percentage points sequentially, as revenue grew faster than expenses in both comparisons. The margin has risen each quarter from 24.35% in Q1FY26 to 28.27% in Q4FY26. Lower interest costs, down 28.30% year on year, also supported pre-tax profit, while the 21.98% tax rate was 3.23 percentage points below last year's level.
Margin remains above the reported healthcare peer median
Laurus Labs' 28.27% operating margin was 4.89 percentage points above the 23.38% median for the 48 Healthcare peers that had reported the same quarter. Sequentially, revenue rose 1.87% and operating profit increased 6.64%, although interest costs rose 4.25% and the tax rate increased 0.60 percentage points from Q3FY26.
Management points to capacity and specialty expansion
Management said the company crossed 8,200 kL of reactor volumes in FY26 and is continuing large-scale API and fermentation capex at Vizag. It said the 532-acre Vizag site is part of an eight-year investment plan exceeding $600 million, with capex expected to begin toward the end of FY27. Management also said a CAR-T GMP facility in Nerul was commissioned in March 2026 with annual treatment capacity of 2,500, while commercial peptide capabilities are being advanced for customer needs.
Initial stock reaction was mild versus Laurus Labs' history
The stock fell 0.47% on the results day and opened with a 1.79% gap down, while its relative return was 0.28%. That day-one move was smaller than the 3.08% median absolute reaction across the past eight results, after which the stock rose six times and fell twice. The recorded return was 5.45% after one session and 11.05% after five sessions.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹1,812 cr | ₹1,778 cr | +1.87% | +5.31% |
| Other income | ₹12 cr | ₹5 cr | +164.46% | -79.15% |
| Expenses | ₹1,299 cr | ₹1,298 cr | +0.11% | -0.02% |
| Operating profit | ₹512 cr | ₹480 cr | +6.64% | +21.76% |
| Operating margin (%) | 28.27% | 27.00% | — | — |
| Interest | ₹40 cr | ₹39 cr | +4.25% | -28.30% |
| Depreciation | ₹122 cr | ₹121 cr | +1.23% | +10.57% |
| Profit before tax | ₹362 cr | ₹325 cr | +11.13% | +16.16% |
| Tax | ₹79 cr | ₹73 cr | +8.18% | +1.26% |
| Net profit | ₹282 cr | ₹252 cr | +11.99% | +21.19% |
| EPS (₹) | ₹5.17 | ₹4.67 | +10.71% | +19.12% |
Operating margin of 28.27% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -0.47% | +0.28% |
| Next session | +5.45% | — |
| 5 sessions | +11.05% | +11.05% |
| 15 sessions | +21.46% | — |
| 30 sessions | +25.59% | — |
Volume on the results session was 1.41× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company crossed 8,200 kL of reactor volumes in FY26.
- The new CAR-T GMP facility in Nerul was commissioned in March 2026.
Guidance & outlook
- The company targets reducing Scope 1+2 emissions by more than 40% and Scope 3 emissions by more than 50% by FY31 versus FY25.
- Asset turns are projected to exceed 1.0x in the medium term.
- Dolutegravir use is expected to remain steady over the next couple of years.
- The company expects sustained clinical and commercial contracting to drive a good growth outlook.
Expansion
- The new 532-acre Vizag site will begin receiving capex toward the end of FY27 under an eight-year investment plan exceeding $600 million.
- The company is continuing capex for large-scale API and fermentation capacity at the Vizag site.
- A new CAR-T GMP facility in Nerul was commissioned in March 2026 and adds 2,500 annual treatment capacity.
New initiatives
- The company is advancing commercial peptide manufacturing capabilities and capacities for customers' future needs.
- The company is investing in green energy projects, including solar and wind projects.
- The company is pursuing global partnerships and licensing pathways for cell therapy.
- Phase 1 trials of BCMA for relapsed or refractory multiple myeloma are ongoing.
Competition
- The company states that it has sustained ARV leadership and services one-third of the global HIV population.
Problems & risks
- The company identifies adherence and retention challenges affecting long-acting injectable adoption.
- The company maintained deliveries despite global supply chain challenges.
- The company is operating amid ongoing supply chain disruption.
What to watch
- Whether consolidated operating margin holds above 28.27% after rising from 24.35% in Q1FY26.
- Updates on management's projected medium-term asset turns of more than 1.0x.
- Progress at the Nerul CAR-T facility against its annual treatment capacity of 2,500.